NGNE
ニューロウジェネスィス
Neurogene Inc.
通常取引データ（自動更新なし）RVOL 0.3xDV $2M20日平均DV $6M?
Earnings 2026-11-1252W high -17.2%52W low +126.9%Fwd PER 5.9xMarket cap $520MAvg volume 172K
Company Overview
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
Earnings & Financials
Earnings actuals
| Period | EPS | Revenue | FCF |
|---|
| 2026 Q2 | -1.53 | $0 | -$24M |
| 2026 Q1 | -1.39 | $0 | -$26M |
| 2025 Q4 | -1.60 | $0 | -$17M |
| 2025 Q3 | -0.99 | $0 | -$20M |
| 2025 Q2 | -1.05 | $0 | -$20M |
| 2025 Q1 | -1.08 | $0 | -$22M |
| 2024 Q4 |
